| CAS NO: | 104206-65-7 |
| 包装 | 价格(元) |
| 10mM (in 1mL DMSO) | 电议 |
| 10mg | 电议 |
| Cas No. | 104206-65-7 |
| 别名 | 尼替西农; NTBC; Nitisone; SC0735 |
| 化学名 | 2-(2-nitro-4-(trifluoromethyl)benzoyl)cyclohexane-1,3-dione |
| Canonical SMILES | FC(F)(F)C1=CC(N(=O)=O)=C(C(C2C(CCCC2=O)=O)=O)C=C1 |
| 分子式 | C14H10F3NO5 |
| 分子量 | 329.23 |
| 溶解度 | ≥ 13.55mg/mL in DMSO |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Nitisinone(SC0735) is an inhibitor of the enzyme 4-hydroxyphenylpyruvate dioxygenase.Target: 4-Hydroxyphenylpyruvate DioxygenaseNitisinone is a drug used to slow the effects of hereditary tyrosinemia type 1. Nitisinone reduced urinary HGA levels from an average of 4.0 +/- 1.8 (SD) g/day to 0.2 +/- 0.2 g/day ( P< .001). Low-dose nitisinone effectively reduced urinary HGA levels in patients with alkaptonuria. Future long-term clinical trials are planned to determine the benefits of nitisinone in preventing joint deterioration and providing pain relief, and its long-term side effects [1]. Nitisinone can prevent the development of liver disease and significantly reduce the risk of developing hepatocellular carcinoma; however, vigorous surveillance for the development of HCC needs to be continued lifelong [2]. References: |
m.cnreagent.com